Clinical trials: Demyelinating Diseases
Multiple Sclerosis
A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis
This is a Phase 1 study of IMS001, given as a single dose to subjects with Multiple Sclerosis who experience inadequate response and/or intolerability to disease modifying treatments.
- Trial name
- NCT04956744
- Testing
- IMS001
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- ImStem Biotechnology
Multiple Sclerosis, Relapsing-Remitting
Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition
This multi-center non-interventional, observational, cross-sectional study in adult participants with relapsing remitting multiple sclerosis (RRMS) will evaluate the participants' preferences for disease modifying treatments…
- Trial name
- NCT02598167
- Where
- 18 sites in Spain
- Volunteers
- 223 people
- Sponsor
- Hoffmann-La Roche
Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥18 years) with RMS, PPMS, or NRSPMS who were previously enrolled in the Phase 2b…
- Conditions
- Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
- Trial name
- NCT06372145
- Testing
- Tolebrutinib, Teriflunomide
- Where
- 352 sites in United States, Argentina and 45 more
- Volunteers
- 2,500 people
- Sponsor
- Sanofi
Multiple Sclerosis
Study of Oral Fampridine-SR in Multiple Sclerosis
To assess the safety and efficacy of 10 milligram (mg) twice a day (b.i.d.) Fampridine-SR in patients diagnosed with multiple sclerosis (MS), in a double-blind, placebo-controlled, parallel group study.
- Trial name
- NCT00127530
- Testing
- Fampridine-SR
- Where
- 34 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Acorda Therapeutics
Multiple Sclerosis, MS
Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects
This is a multi-center, two-arm non-comparative, observational, 96 week Phase IV study to evaluate treatment adherence when using RebiSmart™ for self-injection of Rebif® in subjects with relapsing multiple sclerosis (RMS).
- Trial name
- MEASURE (NCT01128075)
- Testing
- RebiSmart™
- Where
- Canada
- Volunteers
- 198 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
A Study of Treatment Patterns and Annualized Relapse Rate in Multiple Sclerosis Patients Who Escalate Versus Continue Disease-Modifying Therapies Following Relapse
The aim of this study was to describe real-world treatment patterns after relapsing on platform disease-modifying therapies (DMTs) in terms of proportions of patients who remain on platform DMTs or escalate to high-efficacy DMTs…
- Trial name
- NCT07743281
- Where
- United States
- Volunteers
- 753 people
- Sponsor
- Novartis Pharmaceuticals
Cognition Disorders, Multiple Sclerosis
A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis
The purpose of this study is to determine the safety and efficacy of C105 in treating the cognitive deficits that can occur due to multiple sclerosis.
- Trial name
- NCT00529581
- Testing
- C105
- Where
- 30 sites in United States
- Volunteers
- 150 people
- Sponsor
- Cognition Pharmaceuticals, LLC
Multiple Sclerosis
TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants
The primary objective of the study is to estimate the incidence of progressive multifocal leukoencephalopathy (PML) and serious adverse events (SAEs) of other opportunistic infections (OIs) among all participants taking…
- Trial name
- NCT05236777
- Testing
- Natalizumab
- Where
- 15 sites in Czechia
- Volunteers
- 675 people
- Sponsor
- Biogen
Spinal Cord Injury, Tetraplegia/Tetraparesis
Evaluation of Usability and Safety of the System Atalante in Patients With High Paraplegia and Tetraplegia
The objective of this clinical trial is to determine whether the Atalante X exoskeleton can be safely utilized by patients with tetraplegia and high paraplegia (at or above T4).
- Conditions
- Spinal Cord Injury, Tetraplegia/Tetraparesis, Paraplegia, Complete, Paraplegia, Incomplete
- Trial name
- QUATRO (NCT06939634)
- Testing
- Hands-free exoskeleton
- Where
- 3 sites in France
- Volunteers
- 35 people
- Sponsor
- Wandercraft
Multiple Sclerosis, Relapsing-Remitting
An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
This open-label, rater-blinded extension study enrolled participants who had relapsing-remitting multiple sclerosis (RRMS) and who participated in one of three prior Genzyme-sponsored studies of alemtuzumab (CAMMS223…
- Trial name
- NCT00930553
- Testing
- alemtuzumab
- Where
- 176 sites in United States, Argentina and 21 more
- Volunteers
- 1,314 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis, Relapsing-Remitting
BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose
The BEYOND Follow-Up study will give patients who participated in the preceding BEYOND study the opportunity to continue treatment with the 500µg dose of interferon beta (IFNB) 1b and will further investigate the safety and…
- Trial name
- Beyond (NCT00459667)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 184 sites in United States, Argentina and 24 more
- Volunteers
- 1,420 people
- Sponsor
- Bayer
Multiple Sclerosis
Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple Sclerosis
The primary objective of this study is to establish scores of Cognitive impairment (CI) of the 3 DigiCog [Brief Computerized Cognitive Assessment for Multiple Sclerosis (BCCAMS) app] tests [Computerized Speed Cognitive Test…
- Trial name
- DigiToms (NCT04756700)
- Testing
- DigiCog (BCCAMS app), Konectom Application
- Where
- France
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Biogen
Multiple Sclerosis
Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis
Study design is double-blind, randomized, placebo-controlled study in 3 parallel groups with the use of active comparator and placebo. Total duration of therapy of about 2 years.
- Trial name
- NCT02727907
- Testing
- BCD-033 (interferon beta 1a), Rebif (interferon beta 1a)
- Where
- Russia
- Volunteers
- 163 people
- Sponsor
- Biocad
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
The primary objective is to establish the safety of administration of intranasal Foralumab in non-active primary and secondary progressive Multiple Sclerosis (MS) patients in a multiple ascending dose format in escalating doses…
- Conditions
- Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Multiple Sclerosis
- Trial name
- NCT05029609
- Testing
- Intranasal Foralumab Solution
- Sponsor
- Tiziana Life Sciences LTD
Muscle Spasticity
Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis
A drug called AV650 (tolperisone HCl) will be given to patients who have spasticity associated with multiple sclerosis. This study has three purposes: 1. To determine whether AV650 is safe for patients with multiple sclerosis; 2.
- Trial name
- NCT00532532
- Testing
- tolperisone HCl
- Where
- 28 sites in Czechia, Germany and 3 more
- Volunteers
- 150 people
- Sponsor
- Avigen
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO.
- Trial name
- NCT02003144
- Testing
- eculizumab
- Where
- 69 sites in United States, Argentina and 18 more
- Volunteers
- 119 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Multiple Sclerosis
A Retrospective Study to Understand the Clinical Management of Subjects With Multiple Sclerosis at a Site in Taiwan Over the Last 10 Years
This is an observational, non comparative, non-randomised, open-label, retrospective, single centre study planned to collect the data of subjects diagnosed with multiple sclerosis (MS) as per Poser or McDonald criteria between…
- Trial name
- NCT01084798
- Where
- Taiwan
- Volunteers
- 123 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy
An observational study to determine the impact of multiple neutralizing antibody (NAb) tests on treatment patterns compared to the usual care of MS patients receiving high-dose IFN therapy.
- Trial name
- NCT00336557
- Testing
- NAbs testing
- Where
- 49 sites in United States
- Volunteers
- 1,230 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Neuromyelitis Optica Spectrum Disorders
An Open Label Study of the Effects of SHR1459 in NMOSDs Patients
This is an open-label study, to evaluate the efficacy and safety of SHR1459 in participants with NMOSDs.
- Trial name
- NCT04670770
- Testing
- Drug - SHR1459
- Where
- 8 sites in China
- Volunteers
- 10 people
- Sponsor
- Reistone Biopharma Company Limited
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
To compare the efficacy of inebilizumab (MEDI-551) versus placebo in reducing the risk of an neuromyelitis optica/neuromyelitis optica- spectrum disorders (NMO/NMOSD) attack in participants with NMO/NMOSD.
- Trial name
- NCT02200770
- Testing
- Inebilizumab
- Where
- 98 sites in United States, Australia and 23 more
- Volunteers
- 231 people
- Sponsor
- MedImmune LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.